Condition: Triple-negative Breast Cancer · Sponsor: First Affiliated Hospital of Zhejiang University
To evaluate the clinical efficacy and safety of oral all-trans retinoic acid in combination with toripalimab in patients with locally advanced, recurrent, or metastatic triple-negative breast cancer who had failed second-line and subsequent therapy.
This description comes directly from the study's public registry record.
Jian Liu, MS · +86-0571-87236537 · lindaliu87@zju.edu.cn
Meihua Lin, MS · mhlin2015@zju.edu.cn
Always discuss trial participation with your own doctor first.
| The first affiliated hospital, Zhejiang University School of Medicine | Hangzhou, Zhejiang Province, P.R. China, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06371274